GlobeNewswire

Largest, Most Popular Business School Programs Worldwide See Application Growth While Smaller Programs Experience Declines

Dela

Programs in Europe, Canada, India, and East and Southeast Asia Witness Gains; U.S. Programs Suffer From Shifting Demand

RESTON, Va., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Nearly 3 in 4 (73 percent) graduate business programs with 201 or more class seats report increased application volumes this year compared to 39 percent of the smallest programs (50 or fewer class seats), according to a new application trends survey from the Graduate Management Admission Council (GMAC). The growth among the larger U.S. programs is driven by a resurgence of domestic applications, offsetting declines in international applicants.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9e12e0d8-1e20-492d-90cd-4a7db8ee7175

Regardless of class size, a majority of programs in Europe, Canada, East and Southeast Asia, and India report growing volumes in 2017, while fewer than half the programs in the United States are growing - with the exception of part-time lockstep MBA and Master in Data Analytics programs.

"Demand for graduate business education remains strong, especially among the largest programs, which tend also to be the most well-known programs with brand recognition," said Sangeet Chowfla, GMAC president and CEO. "While non-U.S. programs are thriving, a strong economy and a disruptive political climate are likely contributing to the downward trend in application volumes among smaller U.S. programs this year."

GMAC conducted its 18th annual Application Trends Survey from early June to mid-July 2017. The survey findings are based on a record number of responses from 351 business schools and faculties located in 40 countries representing 965 graduate management programs, including MBA, non-MBA business master's, and doctoral-level programs. Participating programs received a combined total of 466,176 applications during the 2017 application cycle. Ninety-two percent of all participating programs report that the applicants this year are similarly or more academically qualified than candidates last year.

U.S. Political Climate Impacts International Application Volumes

Recent political events in the U.S. appear to have impacted application volumes from international candidates in 2017. Programs in Europe and Canada are about twice as likely to report growth in international applicants compared with the U.S. Across all program types, just 32 percent of U.S. programs report growing international application volumes in 2017 vs. 49 percent in 2016. Conversely, seventy-seven percent of Canadian programs report increases in international applications (46 percent in 2016), as well as 67 percent of European programs (65 percent in 2016). Despite the Brexit vote, about two-thirds of programs in the United Kingdom have seen international demand grow.

Overall, the 2017 report findings show that international applicants represent 57 percent of U.S. application volumes, 70 percent of Canadian volume, 89 percent of European volume, 20 percent of East and southeast Asian volume, and less than one percent of Indian volume.

Domestic candidates remain an area of strength for the larger, well known U.S. programs. Sixty-nine percent of programs with class sizes of more than 200 report growth in domestic applications, offsetting the fact that only 38 percent of programs similar in size report growth in international applications.

Women Make Gains in Applicant Pool

The results of the GMAC Application Trends Survey Report 2017 show that women are increasing their representation in the graduate business school pipeline. Today, women represent 42 percent of the total applications received by participating survey programs, up from 37 percent in 2013. Most program types have experienced an increase in the representation of women in the application pipeline. Specifically, among MBA programs women represent 39 percent of applications, up from 33 percent in 2013. More MBA programs report growth in female applicants (44 percent) compared with business master's (39 percent), whereas the growth rate is similar for men - 40 percent for MBA and 39 percent for business master's.

Additional Key Findings

  • Overall volume to the general part-time MBA program category has been stagnant or on the decline since the Great Recession. Part-time lockstep programs - in which students proceed through a classroom-based program as a group - have seen stronger application volumes than part-time self-paced programs, in which students set their own schedule in a flexible format. Among U.S. part-time MBA programs, 54 percent of lockstep programs report increased volume this year, compared with just 34 percent of self-paced programs.
  • Most graduate business programs expect to see employer sponsorship remain stable. About half (52 percent) of part-time, self-paced students are expected to receive employer support, as are 40 percent of executive MBA and 39 percent of part-time lock-step MBA students.
  • The level of experience that the applicant brings to the graduate business program has remained relatively consistent in 2017 compared with five years ago. For example, the majority of full-time MBA applicants have between three and 10 years of experience; the majority of executive MBA applicants have 10 or more years of experience; and most online MBA applicants have six or more years of experience.
  • Among business master's programs, applicants tend to have less than one year of work experience; the exception is the Master in Data Analytics candidate who tends to have more experience.

To download GMAC's Application Trends Survey Report 2017 visit: gmac.com/applicationtrends.
For supporting graphics, visit the GMAC News Center.

About GMAC: The Graduate Management Admission Council (GMAC) is a global, non-profit association of 220 leading graduate business schools. Founded in 1953, we are actively committed to advancing the art and science of admissions by convening and representing the industry and offering best-in-class products and services for schools and students. GMAC owns and administers the Graduate Management Admission Test® (GMAT®) exam, used by more than 6,500 graduate programs worldwide. Other GMAC assessments include the NMAT by GMAC(TM) exam, for entrance into graduate management programs in India and South Africa, and the Executive Assessment, specifically designed for Executive MBA programs around the world. The Council is based in the United States with offices in the United Kingdom, India, and Hong Kong. For information on assessments, study tools and services for candidates, visit www.mba.com. For information about The Council and our market intelligence, professional development opportunities and services for graduate management education, please visit www.gmac.com

MEDIA CONTACT:  
Jennifer Garfinkel; Director of Media Relations, GMAC
+1 (703) 668-9805 or jgarfinkel@gmac.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Graduate Management Admission Council via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum